Intellia Therapeutics
Logotype for Intellia Therapeutics Inc

Intellia Therapeutics (NTLA) investor relations material

Intellia Therapeutics Jefferies Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Intellia Therapeutics Inc
Jefferies Global Healthcare Conference summary17 Nov, 2026

HAE regulatory and clinical update

  • Lonvo-z is under priority FDA review, with a March 10, 2027 PDUFA date; FDA has said so far that an advisory committee is not needed, and review has proceeded without unusual requests.

  • The CMC review is progressing well through the FDA pilot program; prior FDA engagement helped establish standards for products like this.

  • HAE data show attacks falling to zero for most patients; all patients across Phase I–III were off long-term prophylaxis, while one outlier with ongoing attacks had essentially normal high-molecular-weight kininogen levels and may have another condition.

  • On-demand therapy use fell sharply from pretreatment levels; kallikrein knockdown follow-up extends beyond 4 years, with continued monitoring planned.

HAE launch and market access

  • Survey research found nearly 70% of patients willing to discuss lonvo-z with physicians in the first 6 months post-approval; about two-thirds of physicians expected to prescribe within the first year.

  • Initial adopters may include both patients seeking better control and well-controlled patients looking to avoid chronic therapy; Phase III outcomes were similar across patient groups.

  • Payer coverage is the launch rate-limiting step: medical exceptions are expected in the first 3 months, initial contracts and treated patients in months 3–6, and a goal of covering most HAE lives by month 9.

  • The U.S. launch is the near-term focus; ex-U.S. options include out-licensing or distribution arrangements, to be considered after establishing the U.S. launch. Management interprets cell and gene therapies as excluded from MFN considerations.

  • Management expects a high-margin, one-time product, citing synthetic manufacturing and established infrastructure; pricing and COGS details were not specified.

TTR program

  • Following the clinical hold lift, multinational sites are being reactivated; investigator enthusiasm is unchanged, patients remained in the study, and HLA status information has helped inform benefit-risk discussions.

  • HLA-positive status runs at 10%–12% across the study, varying with ethnicity and geography.

  • MAGNITUDE-2 enrollment is complete, with enrollment described as roughly 10%–15% above the target of about 60; a 9-month interim is under consideration but is not currently planned.

  • In Phase I polyneuropathy follow-up through 2 years, some patients stabilized or improved, including several who had progressed on Onpattro; Phase III is placebo-controlled, so direct comparisons with other therapies are not planned.

  • Cardiomyopathy Phase III enrollment is progressing ahead of schedule; management is evaluating potential study adjustments using external trial results and emphasizing earlier-stage patients with lower NT-proBNP.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Intellia Therapeutics earnings date

Logotype for Intellia Therapeutics Inc
Q4 202625 Feb, 2027
Intellia Therapeutics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Intellia Therapeutics earnings date

Logotype for Intellia Therapeutics Inc
Q4 202625 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's therapies are based on a targeted genome editing platform, including CRISPR/Cas9 and proprietary next-generation programmable nucleases (PNs), which can induce a range of large deletions, substitutions or insertions across a target gene. The CRISPR/Cas9 genome editing technology has been shown to be effective in editing genomes in multiple cell types and organisms. Intellia Therapeutics was founded in 2013 and is based in Cambridge, Massachusetts.